Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever.

PloS One
Andrea MarziAyato Takada

Abstract

Ebola virus (EBOV) is the causative agent of severe hemorrhagic fever in primates, with human case fatality rates up to 90%. Today, there is neither a licensed vaccine nor a treatment available for Ebola hemorrhagic fever (EHF). Single monoclonal antibodies (MAbs) specific for Zaire ebolavirus (ZEBOV) have been successfully used in passive immunization experiments in rodent models, but have failed to protect nonhuman primates from lethal disease. In this study, we used two clones of human-mouse chimeric MAbs (ch133 and ch226) with strong neutralizing activity against ZEBOV and evaluated their protective potential in a rhesus macaque model of EHF. Reduced viral loads and partial protection were observed in animals given MAbs ch133 and ch226 combined intravenously at 24 hours before and 24 and 72 hours after challenge. MAbs circulated in the blood of a surviving animal until virus-induced IgG responses were detected. In contrast, serum MAb concentrations decreased to undetectable levels at terminal stages of disease in animals that succumbed to infection, indicating substantial consumption of these antibodies due to virus replication. Accordingly, the rapid decrease of serum MAbs was clearly associated with increased viremia in n...Continue Reading

References

Oct 1, 1987·Microbial Pathogenesis·D M MorensN J Marchette
Apr 16, 1996·Proceedings of the National Academy of Sciences of the United States of America·A SanchezS T Nichol
Feb 7, 1998·Proceedings of the National Academy of Sciences of the United States of America·A TakadaY Kawaoka
Oct 13, 2001·Trends in Microbiology·A Takada, Y Kawaoka
Jun 14, 2003·Journal of Virology·Ayato TakadaYoshihiro Kawaoka
Nov 20, 2003·Reviews in Medical Virology·Ayato Takada, Yoshihiro Kawaoka
Apr 23, 2004·The EMBO Journal·Olga DolnikViktor Volchkov
Sep 24, 2004·Expert Reviews in Molecular Medicine·Thomas W Geisbert, Lisa E Hensley
Oct 24, 2006·Vaccine·Ayato TakadaYoshihiro Kawaoka
Jan 24, 2007·PLoS Pathogens·Wendelien B OswaldDennis R Burton
Jun 26, 2007·Nature Reviews. Immunology·Mansour MohamadzadehAlan L Schmaljohn
Dec 6, 2007·The Journal of Infectious Diseases·Ayato TakadaYoshihiro Kawaoka
Nov 22, 2008·PLoS Pathogens·Jonathan S TownerStuart T Nichol
Jan 10, 2009·Disease Models & Mechanisms·Dennis BenteHeinz Feldmann
Dec 17, 2009·Biotechnology and Bioengineering·Min ZhangMatthew V Caple
Sep 24, 2010·Clinical and Vaccine Immunology : CVI·Eri NakayamaAyato Takada
Nov 19, 2010·Lancet·Heinz Feldmann, Thomas W Geisbert
Mar 18, 2011·Journal of Virology·Masfique MehediHeinz Feldmann
Oct 19, 2011·The Journal of Infectious Diseases·Eri NakayamaAyato Takada
Nov 22, 2011·Nature Structural & Molecular Biology·João M DiasErica Ollmann Saphire
Mar 1, 2012·Frontiers in Microbiology·Ayato Takada

❮ Previous
Next ❯

Citations

Nov 6, 2013·Immunotherapy·Erica Ollmann Saphire
Jan 16, 2013·Proceedings of the National Academy of Sciences of the United States of America·Andrea MarziIlhem Messaoudi
Jan 1, 2012·Uirusu·Ayato Takada
Feb 7, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Stanley A Plotkin
Jan 31, 2016·Current Opinion in Virology·Larry ZeitlinGary P Kobinger
Apr 20, 2014·Expert Review of Clinical Immunology·Gary WongXiangguo Qiu
Jun 13, 2015·Expert Opinion on Investigational Drugs·Gary Wong, Xiangguo Qiu
Feb 11, 2016·Scientific Reports·Wakako FuruyamaAyato Takada
Apr 18, 2015·Journal of the Formosan Medical Association = Taiwan Yi Zhi·Samson Sai-Yin Wong, Sally Cheuk-Ying Wong
Nov 19, 2014·Proceedings of the National Academy of Sciences of the United States of America·Charles D MurinErica Ollmann Saphire
Feb 28, 2015·Cell·Takao HashiguchiErica Ollmann Saphire
Feb 28, 2015·Cell·Andrew I FlyakJames E Crowe
Mar 11, 2016·Science Translational Medicine·Xiangguo QiuGary P Kobinger
Oct 2, 2015·Viruses·Scott M Anthony, Steven B Bradfute
May 25, 2015·Medical Hypotheses·Joachim Denner
May 8, 2015·The Journal of Infectious Diseases·Joseph PrescottHeinz Feldmann
May 8, 2015·ACS Infectious Diseases·Andrea Rivera, Ilhem Messaoudi
Feb 24, 2015·The Journal of Venomous Animals and Toxins Including Tropical Diseases·Jean-Philippe ChippauxAlejandro Alagón
Feb 8, 2014·Human Vaccines & Immunotherapeutics·Xiangguo Qiu, Gary P Kobinger
Jul 28, 2015·Future Virology·Marina Jerebtsova, Sergei Nekhai
Jul 28, 2016·The Journal of Infectious Diseases·Reiko YoshidaAyato Takada
Oct 17, 2012·Proceedings of the National Academy of Sciences of the United States of America·Gene Garrard OlingerLarry Zeitlin
Jan 24, 2017·Nature Reviews. Immunology·Joseph B PrescottSonja M Best
May 18, 2016·Scientific Reports·Qi ZhangLinqi Zhang
Nov 22, 2012·Viruses·Steven B BradfuteMike Bray
Nov 22, 2012·Viruses·Brian M FriedrichGene G Olinger
Mar 4, 2018·The Journal of Biological Chemistry·Elisabeth K NyakaturaJonathan R Lai
Jun 26, 2018·The Journal of General Virology·Aroon SupramaniamLara J Herrero

❮ Previous
Next ❯

Datasets Mentioned

BETA
AF086833

Methods Mentioned

BETA
phage display
genetic modification
enzyme-linked immunosorbent assay
ELISA
PCR
transfection
phosphotransferase

Software Mentioned

Discovery Studio

Related Concepts

Related Feeds

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.

Argentine Hemorrhagic Fever

Argentine hemorrhagic fever (AHF) is an endemo-epidemic disease caused by junín virus (JUNV), a member of the arenaviridae family. Discover the latest research on AHF here.